Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: An approach to a personalized medicine

Arthritis Care and Research

Volumn 65, Issue 1, 2013, Pages 94-100

  Gremese, Elisa ^a   Carletto, Antonio ^b   Padovan, Melissa ^c   Atzeni, Fabiola ^d   Raffeiner, Bernd ^e   Giardina, Anna Rita ^f   Favalli, Ennio Giulio ^g   Erre, Gian Luca ^h   Gorla, Roberto ⁱ   Galeazzi, Mauro ^j   Foti, Rosario ^k   Cantini, Fabrizio ^l   Salvarani, Carlo ^m   Olivieri, Ignazio ⁿ   Lapadula, Giovanni ^o   Ferraccioli, Gianfranco ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f UNIVERSITY OF PALERMO   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h UNIVERSITY OF SASSARI   (Italy)

ⁱ SPEDALI CIVILI   (Italy)

^j UNIVERSITY OF SIENA   (Italy)

^k UNIVERSITY OF CATANIA   (Italy)

^l Prato Hospital   (Italy)

^m S MARIA NUOVA HOSPITAL   (Italy)

ⁿ SAN CARLO HOSPITAL   (Italy)

^o UNIVERSITY OF BARI   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; ETANERCEPT; IMMUNOGLOBULIN M; INFLIXIMAB; METHOTREXATE; RHEUMATOID FACTOR;

ADULT; ARTICLE; BODY MASS; DAS28; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; OBESITY; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PERSONALIZED MEDICINE; REMISSION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; TREATMENT DURATION;

AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGLOBULIN G; INDIVIDUALIZED MEDICINE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OBESITY; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; REMISSION INDUCTION; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84871821443     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21768     Document Type: Article

References (31)

1. Ouchi N, Parker JL, Lugus JJ, Walsh K,. Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011; 11: 85-97.
2. Ferraccioli G, Gremese E,. Adiposity, joint and systemic inflammation: the additional risk of having a metabolic syndrome in rheumatoid arthritis. Swiss Med Wkly 2011; 141: w13211.
3. Eaton CB,. Obesity as a risk factor for osteoarthritis: mechanical versus metabolic. Med Health R I 2004; 87: 201-4.
4. Lohmander LS, Felson D,. Can we identify a 'high risk' patient profile to determine who will experience rapid progression of osteoarthritis? Osteoarthritis Cartilage 2004; 12 Suppl: S49-52.
5. Voigt LF, Koepsell TD, Nelson JL, Dugowson CE, Daling JR,. Smoking, obesity, alcohol consumption, and the risk of rheumatoid arthritis. Epidemiology 1994; 5: 525-32.
6. Stavropoulos-Kalinoglou A, Metsios GS, Panoulas VF, Nevill AM, Jamurtas AZ, Koutedakis Y, et al. Underweight and obese states both associate with worse disease activity and physical function in patients with established rheumatoid arthritis. Clin Rheumatol 2009; 28: 439-44.
7. Symmons DP, Bankhead CR, Harrison BJ, Brennan P, Barrett EM, Scott DG, et al. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum 1997; 40: 1995-61.
8. Bartfai T, Waalen J, Buxbaum JN,. Adipose tissue as a modulator of clinical inflammation: does obesity reduce the prevalence of rheumatoid arthritis? J Rheumatol 2007; 34: 488-92.
9. Van der Helm-van Mil AH, van der Kooij SM, Allaart CF, Toes RE, Huizinga TW,. A high body mass index has a protective effect on the amount of joint destruction in small joints in early rheumatoid arthritis. Ann Rheum Dis 2008; 67: 769-74.
10. Garcia-Poma A, Segami MI, Mora CS, Ugarte MF, Terrazas HN, Rhor EA, et al. Obesity is independently associated with impaired quality of life in patients with rheumatoid arthritis. Clin Rheumatol 2007; 26: 1831-5.
11. Klaasen R, Wijbrandts CA, Gerlag DM, Tak PP,. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum 2011; 63: 359-64.
12. Lapadula G, Ferraccioli G, Ferri C, Punzi L, Trotta F,. GISEA: an Italian biological agents registry in rheumatology. Reumatismo 2011; 63: 155-64.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
14. National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI). Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults: the evidence report. Obes Res 1998; 6 Suppl: 51S-209S.
15. Calle EE, Thun MJ, Petrelli JM, Rodriguez C, Heath CW Jr,. Body mass index and mortality in a prospective cohort of US adults. N Engl J Med 1999; 341: 1097-105.
16. Adams KF, Schatzkin A, Harris TB, Kipnis V, Mouw T, Ballard-Barbash R, et al. Overweight, obesity and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 2006; 355: 763-78.
17. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM,. Prevalence of overweight and obesity in the United States. JAMA 2006; 295: 1549-55.
18. Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, Kitas GD,. Obesity in rheumatoid arthritis. Rheumatology (Oxford) 2011; 50: 450-62.
19. Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, Nevill AM, Douglas KM, Jamurtas A, et al. Redefining overweight and obesity in rheumatoid arthritis patients. Ann Rheum Dis 2007; 66: 1316-21.
20. De Rooy DP, van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH,. Predicting arthritis outcomes: what can be learned from the Leiden Early Arthritis Clinic? Rheumatology (Oxford) 2011; 50: 93-100.
21. Escalante A, Haas RW, del Rincon I,. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 2005; 165: 1624-9.
22. Badley EM, Ansari H,. Arthritis and arthritis-attributable activity limitations in the United States and Canada: a cross-border comparison. Arthritis Care Res (Hoboken) 2010; 62: 308-15.
23. Westhoff G, Rau R, Zink A,. Radiographic joint damage in early rheumatoid arthritis is highly dependent on body mass index. Arthritis Rheum 2007; 56: 3575-82.
24. Jawaheer D, Olsen J, Lahiff M, Forsberg S, Lahteenmaki J, da Silveira IG, et al, for QUEST-RA. Gender, body mass index and rheumatoid arthritis disease activity: results from the QUEST-RA study. Clin Exp Rheumatol 2010; 28: 454-61.
25. Heimans L, van den Broek M, Dirven L, Schouffer AA, Speyer I, Kerstens PJ, et al. Body mass index is associated with decreased response to initial and delayed treatment with dose escalated infliximab in patients with recent onset rheumatoid arthritis [abstract]. Arthritis Rheum 2011; 63 Suppl: S156-7.
26. Smolen JS, Szumski S, Koening AS, Jones TV,. Impact of body mass index on response to etanercept therapy in subjects with moderately active rheumatoid arthritis in the PRESERVE trial [abstract]. Arthritis Rheum 2011; 63 Suppl: S154.
27. Gremese E, Ferraccioli G,. The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk. Autoimmun Rev 2011; 10: 582-9.
28. Nurmohamed MT, Kitas G,. Cardiovascular risk in rheumatoid arthritis and diabetes: how does it compare and when does it start? Ann Rheum Dis 2011; 70: 881-3.
29. Lindharsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Torp-Pedersen C, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Ann Rheum Dis 2011; 70: 929-34.
30. Das UN,. Is obesity an inflammatory condition? Nutrition 2001; 17: 953-66.
31. Isaacs JD, Ferraccioli GF,. The need for personalized medicine for rheumatoid arthritis. Ann Rheum Dis 2011; 70: 4-7.